60 Degrees Pharmaceuticals (60P) has announced the US Food and Drug Administration (FDA) approval of Arakoda (tafenoquine) tablets for the prevention of malaria in patients aged 18 years and older. For the first time in more than eighteen years, the US FDA approved a new drug for the prevention of malaria. Millions of healthy individuals travel to areas where malaria is endemic, including those traveling for leisure, employees of non-governmental organizations, industrial and business workers, and military forces. Arakoda has the potential to protect thousands of US travelers from the devastating and life-threatening effects of malaria. The marketing approval of Arakoda is the culmination of years of scientific discovery and research by experts in the field of Malariology and Infectious Disease. Tafenoquine was originally discovered by scientists at the Walter Reed Army Institute of Research (WRAIR). The approval was based on a concerted effort by the US Army and 60P, involving over 21 clinical trials and over 3,100 trial subjects, to develop tafenoquine as a weekly prophylactic drug for the prevention of malaria. “We have worked closely with the US Army as their commercial partners to bring Arakoda to the US market,” said Geoffrey Dow, Ph.D, CEO of 60P. “Arakoda provides effective protection against both of the major types of malaria (P. vivax and P. falciparum), killing the parasites in both the blood and liver.
“Dow continued, “this provides the travel medicine community the option to prescribe an anti-malarial which provides protection in a large spectrum of malaria hot zones while utilizing what is considered by many physicians to be a more compliant dosing regimen. Arakoda is a significant addition to the armamentarium for the prevention of malaria.” MAJ Victor Zottig, the product manager of tafenoquine for the US Army Medical Materiel Development Activity stated “the FDA approval is a tremendous achievement for 60P and the US military for their long, dedicated effort in the global protection of Service Members and civilian personnel against malaria.” Arakoda is supplied in 100 mg tablets for oral use only. After an initial loading dose prior to traveling, Arakoda is intended to be taken once a week which could offer convenience to the traveler. The US FDA Anti-Microbial Drugs Advisory Committee recently recommended the approval of Arakoda for the prevention of malaria based on its safety and efficacy profile. 60P has committed to the US FDA to perform post-marketing safety surveillance studies to continue to gather data on this important tool against malaria.
Source : www.pharmabiz.com
Published on: August 14, 2018